|
Our New Pick Is Grabbing Headlines…
Great Plains Holdings, Inc. (symbol: GTHP)
Hello Traders,
If you are going to catch a company on its way up, then GTHP is the sort of company you want to catch.
The medical technology company has a very strong news profile which includes the recent closing of a deal worth $10 million.
GTHP is also engaging the FDA for approval of its LuViva® Advanced Cervical Scan and recently presented a plan for advancing the pre-market approval (PMA) application.
There’s more on the FDA goodness below but know that at 6 cents a share there hasn’t been a better time to make a move on this company.
There’s considerable bounce opportunity which combined with the strong news could send GTHP on a huge run north.
You needn’t worry about entry and exit opportunities either: GTHP is experiencing very strong daily volatility providing us with significant windows.
It all makes for a great potential showing so make your move ASAP.
Check Out These 5 Key Short Term Technicals
1. GTHP has some of the strongest bounce potential we’ve seen in the medical technology play and is trading with a RSI of 30.
2. GTHP showcased its upside in July when in one session it delivered intraday gains of up to 27%. This after rallying to a high of .14.
3. GTHP recently announced second quarter 2015 financial results and confirmed a recent deal closed worth $10 million.
4. GTHP has seen daily volatility explode in recent weeks. Average volume of 565K recently gave way to a 1.2 million share breakout.
5. GTHP is trading below its 50 DMA of .11, suggesting potential undervaluation of up to 83% over the short term.
Company Website: http://www.guidedinc.com/
The US Is Still The Largest Market For Medical Devices
The United States remains the largest medical device market in the world with a market size of around $110 billion, and it is expected to reach $133 billion by 2016. The U.S. market value represented about 38 percent of the global medical device market in 2012. U.S. exports of medical devices in key product categories identified by the Department of Commerce (DOC) exceeded $44 billion in 2012, a more than 7 percent increase from the previous year.
Guided Therapeutics Advances LuViva PMA Application with FDA
GTHP has presented the U.S. Food and Drug Administration (FDA) with a plan for advancing the pre-market approval (PMA) application for the LuViva® Advanced Cervical Scan. In its “pre-submission” letter, the Company also requested a meeting with the agency to finalize the plan.
At the suggestion of the FDA, the Company plans to collect additional scans on patients within the context of new cervical cancer screening guidelines recently published by the American Cancer Society, the American Society for Colposcopy and Cervical Pathology, and the American Society for Clinical Pathology.
The letter provides a proposal for a confirmatory study to supplement data previously provided to the agency. In the meeting, the company hopes to gain agreement from the FDA on the study design.
Big Catalysts for GTHP
· GTHP recently closed a deal worth $10 million.
· GTHP has pulled back from recent highs, presenting huge short term upside opportunity for traders.
· GTHP has a very strong news profile which is creating a surge in interest from investors.
Start your research on GTHP now.
Able Trader
|
